Skip Navigation
Print This Page
Share this page: More

Search Results

G0076HH A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and ABT-888 (Velaparib) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Protocol Number:
Phase I/II
Deborah Armstrong
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of ABT-888 when combined with cisplatin and paclitaxel in women with advanced, persistent, or recurrent cervical cancer. - To examine the safety of administering ABT-888 when combined with cisplatin and paclitaxel. -Once the recommended phase II dose is established, this study will aim to estimate the efficacy of cisplatin, paclitaxel, and ABT-888 with respect to objective tumor response in patients with advanced, persistent or recurrent carcinoma of the cervix.
- Primary stage IVB, recurrent or persistent cervix ca - Must have prior chemo/radiation for Phase I portion - 6 weeks out from chemo/radiation - Adjuvant chemo following chemo/rt allowed up to 4 cycles - must have measurable disease for Phase II
Day 1 â?? Taxol over 3 hrs Day 2 â?? Cisplatin over 1 hr Days 1-7 â?? Oral ABT-888 (parp inhibitor) Cycle equal to 21 days
Last Update
08/23/2014 04:02 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer